Vontobel Holding Ltd. Sells 1,708 Shares of Kenvue Inc. $KVUE

Vontobel Holding Ltd. lessened its position in shares of Kenvue Inc. (NYSE:KVUE) by 3.7% in the second quarter, Holdings Channel.com reports. The firm owned 44,036 shares of the company’s stock after selling 1,708 shares during the period. Vontobel Holding Ltd.’s holdings in Kenvue were worth $922,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in KVUE. Pittenger & Anderson Inc. bought a new position in Kenvue during the 1st quarter worth about $30,000. Trust Co. of Vermont grew its holdings in shares of Kenvue by 266.8% in the 2nd quarter. Trust Co. of Vermont now owns 1,581 shares of the company’s stock valued at $33,000 after acquiring an additional 1,150 shares in the last quarter. TruNorth Capital Management LLC bought a new position in shares of Kenvue in the 1st quarter valued at about $36,000. Truvestments Capital LLC bought a new position in shares of Kenvue in the 1st quarter valued at about $37,000. Finally, Clal Insurance Enterprises Holdings Ltd grew its holdings in shares of Kenvue by 378.5% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company’s stock valued at $39,000 after acquiring an additional 1,287 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Kenvue Trading Down 1.0%

Shares of NYSE:KVUE opened at $16.68 on Monday. The company has a 50-day simple moving average of $19.15 and a 200 day simple moving average of $21.31. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.68 and a current ratio of 0.98. The company has a market capitalization of $32.00 billion, a P/E ratio of 22.53, a price-to-earnings-growth ratio of 2.39 and a beta of 0.72. Kenvue Inc. has a 52-week low of $15.47 and a 52-week high of $25.17.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.01. The firm had revenue of $3.84 billion during the quarter, compared to the consensus estimate of $3.94 billion. Kenvue had a net margin of 9.37% and a return on equity of 20.06%. The business’s revenue for the quarter was down 4.0% compared to the same quarter last year. During the same period last year, the business posted $0.32 earnings per share. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Sell-side analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Stockholders of record on Wednesday, August 13th were given a $0.2075 dividend. The ex-dividend date was Wednesday, August 13th. This is a positive change from Kenvue’s previous quarterly dividend of $0.21. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.0%. Kenvue’s dividend payout ratio (DPR) is presently 112.16%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on KVUE shares. Redburn Partners set a $22.00 price objective on Kenvue in a report on Friday, September 26th. Weiss Ratings restated a “hold (c)” rating on shares of Kenvue in a report on Saturday, September 27th. Royal Bank Of Canada cut their target price on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a research note on Friday, August 8th. Zacks Research upgraded shares of Kenvue to a “strong sell” rating in a research note on Monday, August 11th. Finally, Citigroup cut their target price on shares of Kenvue from $20.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, nine have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $21.18.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.